Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2012

View Archived Issues

Researchers at Allergan prepare new S1P1 receptor ligands

TiGenix reports on phase I Cx-621 trial

Tissue Therapies provides update on CE mark application for wound-healing product

PAION receives government grant for thrombomodulin mutants

DiscoveryBioMed receives funding to support metabolic diseases drug discovery program

Safety results presented on new MedImmune immunotherapeutic

AMG-900 shows promise in first-in-human trial

Scientists discover cause of Sengers syndrome / News in Context

Navitoclax administered with bendamustine/rituximab in phase I study

Dinaciclib is highly active in phase I trial in chronic lymphocytic leukemia

ImmunoCellular Therapeutics to expand enrollment in ICT-107 trial

FDA grants priority review for ocriplasmin BLA

Alla Chem discloses novel antivirals

New agents for leukemia developed in U.S.

Novel chemokine receptor antagonists patented by Emory University

New beta-amyloid inhibitors designed in Japan

Constellation Pharmaceuticals presents new inhibitors of bromodomain-containing proteins

Biogen Idec and Isis to collaborate on myotonic dystrophy program

Ferring Pharmaceuticals gains licensing rights to IBAT inhibitor

Takeda reports novel anticancer agents

Drug discovery collaboration begins for postpartum hemorrhage

BioDelivery Sciences reports on BEMA-buprenorphine/naloxone study

Leukemia & Lymphoma Society and Celator expand partnership

CBio discloses planned merger

FDA accepts NDA for once-weekly contraceptive patch

EC decides in favor of SkyePharma product's approval for asthma

Spectrum Pharmaceuticals launches phase II lucanthone trial

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...